For the year ending 2025-12-31, FOLD made $634,210K in revenue. -$27,110K in net income. Net profit margin of -4.27%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Net product sales | 634,210 | |||
| Cost of goods sold | 72,929 | |||
| Gross profit | 561,281 | |||
| Research and development | 135,843 | |||
| Selling, general, and administrative | 383,487 | |||
| Changes in fair value of contingent consideration payable | 0 | |||
| Loss on impairment of assets | 1,702 | |||
| Restructuring charges | 0 | |||
| Depreciation and amortization | 7,460 | |||
| Total operating expenses | 528,492 | |||
| Income (loss) from operations | 32,789 | |||
| Interest income | 3,317 | |||
| Interest expense | 46,159 | |||
| Loss on extinguishment of debt | 0 | |||
| Other (expense) income | 10,244 | |||
| Income (loss) before income tax | 191 | |||
| Income tax expense | 27,301 | |||
| Net loss attributable to common stockholders | -27,110 | |||
| Net loss attributable to common stockholders per common share - basic (in dollars per share) | -0.09 | |||
| Net loss attributable to common stockholders per common share - diluted (in dollars per share) | -0.09 | |||
| Weighted-average common shares outstanding - basic (in shares) | 308,363,768 | |||
| Weighted-average common shares outstanding - diluted (in shares) | 308,363,768 | |||
AMICUS THERAPEUTICS, INC. (FOLD)
AMICUS THERAPEUTICS, INC. (FOLD)